Sarepta Therapeutics,, Inc. Common Stock (SRPT) Stock Price

SRPTStock

$18.92−10.34%52W

Market Cap$2.00B

P/E7.77x

PEG Ratio-0.09

Div yield—

Beta0.32

SRPT Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-12.61%

Price vs S&P 500 (4W)14.45%

PEG Ratio-0.09

VGM Score50.75

P/E Ratio (Annual)7.77x

Book Value / Share (Quarterly)$14.46

P/TBV (Annual)2.03x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)33.07%

Cash Flow / Share (Quarterly)$0.71

Price vs S&P 500 (YTD)-27.71%

Gross Margin (TTM)67.47%

Net Profit Margin (TTM)-6.93%

EPS (TTM)$-1.82

10-Day Avg Trading Volume2.37M

EPS Excl Extra (TTM)$-1.82

Revenue Growth (5Y)32.41%

EPS (Annual)$-7.13

ROI (Annual)-36.22%

Gross Margin (Annual)69.33%

Net Profit Margin (5Y Avg)-39.65%

Cash / Share (Quarterly)$7.47

P/E Basic Excl Extra (TTM)27.89x

Revenue Growth QoQ (YoY)-34.34%

P/E Normalized (Annual)7.77x

ROA (Last FY)-21.30%

Revenue Growth TTM (YoY)-20.44%

EBITD / Share (TTM)$-1.14

ROE (5Y Avg)-67.48%

Operating Margin (TTM)-6.40%

Cash Flow / Share (Annual)$-3.00

P/B Ratio1.27x

P/B Ratio (Quarterly)1.24x

Net Income / Employee (Annual)$-854,400

EV / Revenue (TTM)1.12x

Net Interest Coverage (TTM)-29.15x

ROA (TTM)-4.14%

EV / EBITDA (TTM)1441.13x

EPS Incl Extra (Annual)$-7.13

Current Ratio (Annual)2.32x

Quick Ratio (Quarterly)2.57x

3-Month Avg Trading Volume3.19M

52-Week Price Return-10.34%

P/E Incl Extra (TTM)27.89x

Revenue / Employee (TTM)$2,364,500

Tangible BV / Share (Quarterly)$14.17

P/S Ratio (Annual)0.88x

Asset Turnover (Annual)0.66x

52-Week High$25.32

Operating Margin (5Y Avg)-37.86%

EPS Excl Extra (Annual)$-7.13

CapEx CAGR (5Y)5.09%

Tangible BV CAGR (5Y)8.24%

26-Week Price Return-1.36%

Quick Ratio (Annual)1.44x

13-Week Price Return6.90%

Total Debt / Equity (Annual)0.73x

Current Ratio (Quarterly)4.42x

Enterprise Value$2.22B

Revenue / Share Growth (5Y)25.96%

Asset Turnover (TTM)0.60x

Book Value / Share Growth (5Y)2.52%

Revenue / Employee (Annual)$2,632,600

Inventory Turnover (Annual)0.81x

Pretax Margin (Annual)-31.94%

Cash / Share (Annual)$8.95

3-Month Return Std Dev55.47%

Gross Margin (5Y Avg)82.32%

Net Income / Employee (TTM)$-163,700

ROE (Last FY)-62.55%

Net Interest Coverage (Annual)2.14x

EPS Basic Excl Extra (Annual)$-7.13

P/FCF (TTM)5.99x

Receivables Turnover (TTM)4.37x

EV / Free Cash Flow (TTM)29.42x

Total Debt / Equity (Quarterly)0.55x

EPS Incl Extra (TTM)$-1.82

Receivables Turnover (Annual)4.40x

ROI (TTM)-6.05%

P/S Ratio (TTM)0.98x

Pretax Margin (5Y Avg)-38.74%

Revenue / Share (Annual)$21.96

Tangible BV / Share (Annual)$10.59

Forward P/E7.46x

Price vs S&P 500 (52W)-28.65%

P/E Ratio (TTM)27.89x

Year-to-Date Return-15.75%

5-Day Price Return0.61%

EPS Normalized (Annual)$-7.13

ROA (5Y Avg)-13.51%

Net Profit Margin (Annual)-32.45%

Month-to-Date Return22.01%

Cash Flow / Share (TTM)$-7.32

EBITD / Share (Annual)$-6.79

Operating Margin (Annual)-31.07%

LT Debt / Equity (Annual)0.73x

P/CF (TTM)17.49x

ROI (5Y Avg)-22.02%

P/E Excl Extra (TTM)27.89x

LT Debt / Equity (Quarterly)0.55x

EPS Basic Excl Extra (TTM)$-1.82

P/TBV (Quarterly)1.27x

P/B Ratio (Annual)1.98x

Inventory Turnover (TTM)0.68x

Pretax Margin (TTM)-6.63%

Book Value / Share (Annual)$10.87

Price vs S&P 500 (13W)4.10%

Beta0.32x

P/FCF (Annual)89.06x

Revenue / Share (TTM)$18.73

ROE (TTM)-9.96%

52-Week Low$14.68

vGradeC

gGradeC

mGradeC

vgmGradeC

SRPT Earnings Surprise History

Q2 252.02est. 1.16

Q3 25-0.13est. -0.37

Q4 25-3.58est. -0.77

Q1 263.16est. 1.05

Q2 260.64est. 0.49

SRPT Analyst Recommendations

May 2026

Jun 2026

Jul 2026

Aug 2026

3.42

3.38

3.45

Industry Peers — Pharmaceuticals(571)

Symbol	Value Score	Growth Score	Momentum Score	Price
SRPTSarepta Therapeutics,, Inc. Common Stock	C	C	C	$18.92
LLYEli Lilly & Co.	D	B	B	$1233.66
JNJJohnson & Johnson	D	C	B	$273.14
ABBVABBVIE INC.	D	C	B	$265.79
MRKMerck & Co., Inc.	D	C	A	$156.45
NVSNovartis AG	C	C	C	$159.98
AZNAstraZeneca PLC	C	B	C	$169.66
NVONovo-Nordisk A/S	B	C	C	$48.66
ABTAbbott Laboratories	C	C	B	$116.13
PFEPfizer Inc.	C	D	C	$28.57
VRTXVertex Pharmaceuticals Inc	D	C	B	$552.85
BMYBristol-Myers Squibb Co.	B	B	B	$67.92
SNYSanofi American Depositary Shares (Each representing one-half of one ordinary share)	B	C	C	$46.02
GSKGSK plc American Depositary Shares (Each representing two Ordinary Shares)	B	C	C	$52.07
REGNRegeneron Pharmaceuticals Inc	C	C	B	$833.56
TAKTakeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)	C	C	C	$18.35
TEVATeva Pharmaceutical Industries Limited American Depositary Shares	C	C	C	$38.10
ONCBeOne Medicines Ltd. American Depositary Shares	D	B	C	$376.37
RPRXRoyalty Pharma plc Class A Ordinary Shares	D	D	B	$62.07
ALNYAlnylam Pharmaceuticals, Inc.	D	A	D	$240.08
ZTSZOETIS INC.	B	C	D	$77.29
INSMInsmed, Inc.	F	A	C	$123.89
ROIVRoivant Sciences Ltd. Common Shares	D	F	B	$36.47
UTHRUnited Therapeutics Corp	C	C	C	$518.53
GMABGenmab A/S ADS	C	C	B	$34.36
VTRSViatris Inc. Common Stock	B	C	B	$16.72
JAZZJazz Pharmaceuticals, Inc.	B	C	B	$260.23
ASNDAscendis Pharma A/S Ordinary Share	D	A	C	$252.99
BBIOBridgeBio Pharma, Inc. Common Stock	F	A	B	$80.40
CORTCorcept Therapeutics Inc.	F	C	A	$123.57
BMRNBioMarin Pharmaceuticals Inc	C	C	C	$66.12
ARWRArrowhead Research Corporation	D	A	B	$88.88
ELANElanco Animal Health Incorporated Common Stock	C	B	B	$25.09
MDGLMadrigal Pharmaceuticals, Inc. Common Stock	D	A	C	$512.16
CYTKCytokinetics Inc.	F	D	B	$77.46
AXSMAxsome Therapeutics, Inc	D	B	C	$205.48
SMMTSummit Therapeutics Inc. Common Stock	F	—	D	$13.36
IONSIonis Pharmaceuticals, Inc. Common Stock	D	D	C	$63.57
ABVXAbivax SA American Depositary Shares	—	—	C	$117.93
RDYDr. Reddy's Laboratories Limited American Depositary Shares	D	D	C	$12.34
PRAXPraxis Precision Medicines, Inc. Common Stock	F	—	B	$368.02
NUVLNuvalent, Inc. Class A Common Stock	—	—	B	$123.96
PTGXProtagonist Therapeutics, Inc	F	B	A	$150.59
SYRESpyre Therapeutics, Inc. Common Stock	—	—	A	$107.36
CRNXCrinetics Pharmaceuticals, Inc.	F	A	A	$84.86
TGTXTG Therapeutics, Inc.	D	B	A	$55.42
ALKSAlkermes Inc. plc	D	C	B	$49.21
RYTMRhythm Pharmaceuticals, Inc. Common Stock	F	B	C	$113.35
ORKAOruka Therapeutics, Inc. Common Stock	F	—	A	$101.82
BLTEBelite Bio, Inc American Depositary Shares	—	—	B	$161.68
COGTCogent Biosciences, Inc. Common Stock	F	—	B	$36.80

About Sarepta Therapeutics,, Inc. Common Stock

Sarepta Therapeutics is a commercial-stage biopharmaceutical company specializing in RNA-targeted and gene therapies for rare neuromuscular disorders. The company has four FDA-approved treatments for Duchenne muscular dystrophy and maintains a pipeline of additional candidates for neuromuscular and other rare diseases. Its integrated business model encompasses discovery through patient delivery of genetic medicines for underserved patient populations.